212 related articles for article (PubMed ID: 3937664)
1. A clinical pharmacological study of a new type of vaginal delivery system for levonorgestrel.
Landgren BM; Johannisson E; Xing S; Aedo AR; Diczfalusy E
Contraception; 1985 Dec; 32(6):581-601. PubMed ID: 3937664
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic and pharmacodynamic investigations with vaginal devices releasing levonorgestrel at a constant, near zero order rate.
Landgren BM; Johannisson E; Masironi B; Diczfalusy E
Contraception; 1982 Dec; 26(6):567-85. PubMed ID: 6820337
[TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamic effects of ethinyl estradiol in women using vaginal devices releasing small doses of levonorgestrel at a constant rate.
Toddyvalla V; Johannisson E; Landgren BM; Cekan SZ; Diczfalusy E
Contraception; 1983 Jul; 28(1):21-39. PubMed ID: 6414759
[TBL] [Abstract][Full Text] [Related]
4. Morphometric study of the human endometrium following continuous exposure to levonorgestrel released from vaginal rings during 90 days.
Johannisson E; Brosens I; Cornillie F; Elder M; White J; Sheppard B; Hourihan H; d'Arcangues C; Belsey EM
Contraception; 1991 Apr; 43(4):361-74. PubMed ID: 1906792
[TBL] [Abstract][Full Text] [Related]
5. The interaction between sex hormone binding globulin and levonorgestrel released from vaginal rings in women.
Cekan SZ; Jia M; Landgren BM; Diczfalusy E
Contraception; 1985 Apr; 31(4):431-9. PubMed ID: 3924477
[TBL] [Abstract][Full Text] [Related]
6. The effect of levonorgestrel administered in large doses at different stages of the cycle on ovarian function and endometrial morphology.
Landgren BM; Johannisson E; Aedo AR; Kumar A; Shi YE
Contraception; 1989 Mar; 39(3):275-89. PubMed ID: 2496951
[TBL] [Abstract][Full Text] [Related]
7. Clinical performance and endocrine profiles with contraceptive vaginal rings containing a combination of estradiol and d-norgestrel.
Mishell DR; Moore DE; Roy S; Brenner PF; Page MA
Am J Obstet Gynecol; 1978 Jan; 130(1):55-62. PubMed ID: 619648
[TBL] [Abstract][Full Text] [Related]
8. Clinical and endocrinologic study of continuous levonorgestrel administration from subcutaneous solid polydimethylsiloxane rods.
Roy S; Stanczyk F; Mishell DR; Lumkin M; Gentzschein E
Contraception; 1980 Jun; 21(6):595-615. PubMed ID: 6775868
[TBL] [Abstract][Full Text] [Related]
9. The effect of deliberate omission of Trinordiol or Microgynon on the hypothalamo-pituitary-ovarian axis.
Smith SK; Kirkman RJ; Arce BB; McNeilly AS; Loudon NB; Baird DT
Contraception; 1986 Nov; 34(5):513-22. PubMed ID: 3102162
[TBL] [Abstract][Full Text] [Related]
10. Prostaglandin production in human endometrium following continuous exposure to low-dose levonorgestrel released from a vaginal ring.
White JO; Sullivan MH; Patel L; Croxtall JD; d'Arcangues C; Belsey EM; Elder MG
Contraception; 1991 Apr; 43(4):401-12. PubMed ID: 1649733
[TBL] [Abstract][Full Text] [Related]
11. Blood levels of levonorgestrel in women following vaginal placement of contraceptive pills.
Alvarez F; Faundes A; Johansson E; Coutinho E
Fertil Steril; 1983 Jul; 40(1):120-3. PubMed ID: 6407876
[TBL] [Abstract][Full Text] [Related]
12. Endometrial effects of levonorgestrel and estradiol: A Scanning electron microscopic study of the luminal epithelium.
Nilsson O; Englund D; Weiner E; Victor A
Contraception; 1980 Jul; 22(1):71-83. PubMed ID: 6774851
[TBL] [Abstract][Full Text] [Related]
13. Hormonal consequences of missing the pill during the first two days of three consecutive artificial cycles.
Landgren BM; Diczfalusy E
Contraception; 1984 May; 29(5):437-46. PubMed ID: 6430642
[TBL] [Abstract][Full Text] [Related]
14. Serum levels of d-norgestrel, luteinizing hormone, follicle-stimulating hormone, estradiol, and progesterone in women during and following ingestion of combination oral contraceptives containing dl-norgestrel.
Brenner PF; Mishell DR; Stanczyk FZ; Goebelsmann U
Am J Obstet Gynecol; 1977 Sep; 129(2):133-40. PubMed ID: 900174
[TBL] [Abstract][Full Text] [Related]
15. Ovulatory dysfunction during continuous administration of low-dose levonorgestrel by subdermal implants.
Faundes A; Brache V; Tejada AS; Cochon L; Alvarez-Sanchez F
Fertil Steril; 1991 Jul; 56(1):27-31. PubMed ID: 1906017
[TBL] [Abstract][Full Text] [Related]
16. Intravaginal and intracervical devices for the delivery of fertility regulating agents.
J Steroid Biochem; 1979 Jul; 11(1B):461-7. PubMed ID: 491617
[TBL] [Abstract][Full Text] [Related]
17. Plasma progesterone levels during long-term treatment with levonorgestrel silastic implants.
Croxatto HB; Diaz S; Pavez M; Miranda P; Brandeis A
Acta Endocrinol (Copenh); 1982 Oct; 101(2):307-11. PubMed ID: 6814139
[TBL] [Abstract][Full Text] [Related]
18. Endometrial vascular features prior to and following exposure to levonorgestrel.
Hourihan HM; Sheppard BL; Belsey EM; Brosens IA
Contraception; 1991 Apr; 43(4):375-85. PubMed ID: 1906793
[TBL] [Abstract][Full Text] [Related]
19. Serum concentrations of estradiol, progesterone, and levonorgestrel are not determinants of endometrial histology or abnormal bleeding in long-term Norplant implant users.
Darney PD; Taylor RN; Klaisle C; Bottles K; Zaloudek C
Contraception; 1996 Feb; 53(2):97-100. PubMed ID: 8838486
[TBL] [Abstract][Full Text] [Related]
20. A comparative study of the effects of an estradiol-releasing vaginal ring combined with an oral gestagen versus transdermal estrogen combined with a levonorgestrel-releasing IUD: clinical findings and endometrial response.
Kalogirou D; Antoniou G; Karakitsos P; Kalogirou O; Antoniou D; Giannikos L
Int J Fertil Menopausal Stud; 1996; 41(6):522-7. PubMed ID: 9010746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
